The treatment of multiple myeloma has evolved rapidly with the use of the immunomodulatory agents thalidomide and lenalidomide as well as the proteasome inhibitor bortezomib. Cavo and colleagues recently reported results of a landmark phase III study comparing thalidomide–dexamethasone with bortezomib–thalidomide–dexamethasone in newly diagnosed multiple myeloma.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Harousseau, J. L. Ten years of improvement in the management of multiple myeloma: 2000–2010. Clin. Lymphoma Myeloma Leuk. 1 0, 424–442 (2010).
Attal, M. et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N. Engl. J. Med. 335, 91–97 (1996).
Attal, M. et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N. Engl. J. Med. 349, 2495–2502 (2003).
Rajkumar, S. V. et al. Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J. Clin. Oncol. 26, 2171–2177 (2008).
Rajkumar, S. V. et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 11, 29–37 (2010).
Harousseau, J. L. et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005–01 phase III trial. J. Clin. Oncol. 28, 4621–4629 (2010).
Mitsiades, N. et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 101, 2377–2380 (2003).
Cavo, M. et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 376, 2075–2085 (2010).
Chanan-Khan, A. A. & Giralt, S. Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. J. Clin. Oncol. 28, 2612–2624 (2010).
Richardson, P. G. et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 116, 679–686 (2010).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
P. G. Richardson is on advisory boards of the following companies: Bristol-Myers Squibb, Celgene, Johnson & Johnson, Millenium and Novartis. K. Anderson is a consultant at the following companies: Bristol-Myers Squibb, Celgene, Onyx, Merck, Millenium and Novartis. J. Laubach declares no competing interests.
Rights and permissions
About this article
Cite this article
Laubach, J., Richardson, P. & Anderson, K. Setting the standard for newly diagnosed multiple myeloma. Nat Rev Clin Oncol 8, 255–256 (2011). https://doi.org/10.1038/nrclinonc.2011.43
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2011.43
